Humanin Dosage Guide: Protocols, Calculator & Safety

A beginner approach to humanin for self-experimenters starts with careful consideration of whether a research peptide is the appropriate intervention at all, because the targets humanin addresses — aging, metabolic dysfunction, neurodegeneration, cellular stress — are approachable through validated interventions with far better evidence bases. If mitochondrial health is the goal, zone 2 cardiovascular training 3-4 times per week is the most robust intervention available in the peer-reviewed literature, producing documented improvements in mitochondrial biogenesis, oxidative capacity, and systemic metabolic health. Resistance training 3-5 times per week preserves muscle mass and mitochondrial function. Adequate protein intake (1.6-2.2 g/kg/day), 7-9 hours of sleep, and appropriate caloric balance support mitochondrial health more than any supplement. These are the baseline, and they should be fully optimized before considering exogenous peptides. If cognitive function is the goal, the evidence base for lifestyle interventions — cardiovascular exercise, Mediterranean-pattern diet, social engagement, cognitive stimulation, hearing and vision correction, treatment of vascular risk factors — is substantially stronger than for any research peptide. If metabolic health is the goal, structured caloric deficit with adequate protein, training, and (when indicated) FDA-approved medications such as Semaglutide or Tirzepatide is the approach with Phase 3 data. For self-experimenters who want to proceed with humanin despite the above, a starting protocol is 1-2 mg subcutaneously daily, typically in the morning, for 4-8 weeks. The wild-type humanin peptide has short plasma half-life, and practical dosing is once daily for convenience rather than for optimal pharmacokinetics. The HNG analog, if available, would theoretically allow lower doses because of its higher potency, but HNG is less commonly stocked by research-peptide vendors and dosing adjustments based on HNG potency are inferential rather than validated. Beginners should not stack humanin with other unvalidated research peptides because the principle of starting with single-agent interventions to distinguish effects is basic experimental hygiene. If you want to know whether humanin is doing something for you, take humanin alone and observe over 4-8 weeks; if you combine it with three other peptides simultaneously, you have lost the ability to attribute any effects you notice to any specific compound. Endpoints to monitor during a beginner humanin cycle are necessarily subjective because the rapid-effect endpoints of a well-tolerated cytoprotective peptide are unlikely to be dramatic at physiologic doses: subjective energy and mood, sleep quality, exercise tolerance, recovery between workouts, and basic metabolic markers (fasting glucose, lipid panel) before and after the cycle. Expectations should be modest. Humanin is not a stimulant, not an anabolic agent, not a sleep aid, and not a nootropic in any immediate sense. The proposed benefits are longer-term changes in stress resistance, metabolic function, and cellular protection that manifest as improved health trajectory rather than acute changes in how you feel today. A beginner cycle that produces no detectable subjective effects is entirely consistent with the peptide working at the mechanistic level it is intended to work at, and is also consistent with it doing nothing at the doses used — the difference is not distinguishable without long-term follow-up. Cycle duration at the beginner dose is typically 4-8 weeks followed by an equivalent or longer washout period. There is no rationale for continuous indefinite humanin dosing as a beginner, and short cycles limit cumulative exposure to an unvalidated research peptide. Monitoring should include basic labs before and after the cycle: complete metabolic panel, CBC, HbA1c and fasting glucose/insulin if metabolic effects are the target, lipid panel, and any condition-specific markers that align with personal goals. Abnormalities on follow-up labs that could be attributed to humanin warrant stopping the peptide and re-evaluating. The beginner protocol is also a stage where expectations about side effects are set: humanin is generally well-tolerated, injection site reactions are common and minor, and significant adverse effects are rare. If you have significant adverse effects, stop the peptide, evaluate for the actual cause, and do not continue on the assumption that the reaction will resolve with dose adjustment.

At the intermediate stage, humanin users have completed one or more beginner cycles without significant adverse effects and are either attempting to optimize response or extending the peptide to new contexts. Intermediate protocols typically involve 2-5 mg subcutaneously daily for 8-12 weeks, sometimes divided into twice-daily dosing (morning and evening) to maintain more sustained plasma levels despite the short half-life of the wild-type peptide. The rationale for twice-daily dosing is that humanin's half-life is short enough that once-daily injection produces substantial troughs, and if receptor-mediated signaling benefits from more continuous exposure, divided dosing may improve biological effect. The counterargument is that pulsatile exposure may mimic endogenous secretion patterns better than continuous exposure, and that the optimal dosing regimen is entirely speculative in the absence of human pharmacokinetic data. Divided dosing doubles the injection burden and increases daily cost, so it should only be pursued if the case for continuous signaling is compelling. Intermediate cycles often include stacking with complementary interventions. Mitochondrial support (L-carnitine 1-2 g daily, NAD precursors at label doses, coenzyme Q10 100-200 mg daily) is a common addition with mechanistic coherence. Growth hormone secretagogues — CJC-1295 with Ipamorelin as the most common combination — are sometimes stacked with humanin in longevity-oriented protocols; the combination has no clinical evidence for superior outcomes but does not have obvious contraindications in healthy adults with normal IGF-1 baseline. Anti-inflammatory interventions (omega-3 fatty acids 2-3 g EPA+DHA daily, curcumin, resveratrol) are often included for general longevity reasons. Exercise is a necessary context — humanin is a mitochondrial-derived peptide linked mechanistically to exercise adaptation, and using humanin without concurrent training misses the natural context in which the peptide evolved. Intermediate users typically have 4-6 structured training sessions per week (resistance, cardiovascular, or combined) and use humanin as an adjunct rather than a replacement for training stimulus. Monitoring at intermediate stages should include more detailed labs than at the beginner stage: comprehensive metabolic panel, lipid panel with ApoB and Lp(a) if longevity is the focus, HbA1c and fasting insulin, inflammatory markers (high-sensitivity CRP), IGF-1 if GH secretagogues are stacked, and condition-specific markers appropriate to individual health status. Follow-up every 3 months during active cycles is a reasonable interval. Cardiovascular monitoring becomes more important as cycles extend: blood pressure should be checked regularly, and any chest discomfort, unusual shortness of breath, or arrhythmia sensation warrants evaluation. While humanin is not known to cause cardiovascular effects, any peptide can alter fluid balance or vascular tone in ways that become relevant in people with underlying risk factors. Duration at intermediate doses is typically 8-12 weeks on, 4-8 weeks off, with cycles repeated 2-3 times per year for longevity-oriented users. Continuous dosing beyond 12 weeks is not supported by any data and increases cumulative exposure to an unvalidated research peptide without clear benefit. Between cycles, some users maintain lower-dose infrequent dosing (1-2 mg twice weekly as a "maintenance" protocol), but this practice has no clinical basis and may simply extend the financial and logistical burden of peptide use without corresponding benefit. Expectations at the intermediate stage should be calibrated by experience from the beginner cycle. If beginner cycles produced no detectable benefit, intermediate dosing is not obligated to produce effects — dose-response relationships for endogenous peptides at supraphysiologic supplementation are not linear, and increasing dose may not increase effect. If beginner cycles produced subtle improvement, intermediate cycles may produce more pronounced effects, but the expectation should remain oriented toward long-term health trajectory rather than acute changes. Intermediate users should also consider combining humanin with a longer-term biomarker program — annual physical, appropriate cancer screening, coronary calcium score if age-appropriate, possibly DEXA for body composition — to contextualize peptide use within a comprehensive health strategy. The peptide is an adjunct, not a core intervention.

Advanced humanin protocols are the domain of experienced self-experimenters who have used the peptide through multiple cycles, have baseline comprehensive health data, and are integrating humanin into sophisticated longevity or performance protocols. Advanced dosing typically involves 5-10 mg subcutaneously daily, sometimes using HNG or other stabilized analogs if available, with cycles extending 12-24 weeks or transitioning to semi-continuous dosing with built-in breaks. There is no clinical evidence supporting advanced dose ranges over intermediate ranges, and the marginal benefit per mg likely diminishes as doses rise into ranges that may exceed the effective pharmacologic window. The case for advanced dosing rests on the assumption that more humanin produces more of the desired effects, which is neither validated nor inherently plausible for a peptide that works through a receptor complex that will saturate at some exposure level. Advanced users often pursue multi-peptide longevity protocols that include humanin alongside other investigational compounds: Epithalon for telomere support, Thymosin Alpha-1 for immune function, BPC-157 and TB-500 for tissue repair, GHK-Cu for skin and connective tissue, CJC-1295 with Ipamorelin for growth hormone support, MOTS-c if commercially available for metabolic support, 5-amino-1MQ for NNMT inhibition, and Methylene Blue for mitochondrial electron transport support. These protocols can run into 10-15 concurrent interventions, which introduces significant complexity in attribution, cost, logistical burden, and combined risk assessment. The principle of keeping the intervention count minimal to distinguish effects becomes nearly impossible to maintain, and advanced users often accept that attribution is lost in exchange for the perceived comprehensive coverage of aging mechanisms. Monitoring at the advanced stage should be substantially more extensive: quarterly labs including comprehensive metabolic panel, CBC, thyroid panel, lipid panel with ApoB and Lp(a), HbA1c and fasting insulin, IGF-1 and IGFBP-3 if relevant to the stack, inflammatory markers (hs-CRP, homocysteine), vitamin D, B12, folate, ferritin, and condition-specific markers. Annual comprehensive evaluation should include cardiovascular risk assessment (coronary calcium score, carotid intima-media thickness, stress testing if indicated), cancer screening appropriate for age and sex (colonoscopy, mammography or prostate screening, skin check), bone density (DEXA), body composition (DEXA), cognitive function (baseline neuropsychological testing if cognitive decline is a concern), and exercise capacity testing (VO2max). The point of this monitoring is to ensure that the long-term humanin and multi-peptide protocol is not producing unexpected effects in any organ system, to detect adverse trends early, and to provide the data needed to adjust the protocol if patterns emerge. Advanced users should also consider the legal and regulatory landscape. Research peptides are sold for research use, not human consumption, and the regulatory status varies by jurisdiction. Physicians providing oversight for research-peptide protocols are operating outside FDA approval and outside most mainstream medical practice; the availability of physicians who will do this has grown in recent years (concierge longevity clinics, functional medicine practitioners, anti-aging clinicians) but varies significantly in quality. A physician involved in a humanin protocol should understand the mechanism, the evidence base, the risks, and the monitoring requirements, not merely write prescriptions for labs and collect fees. Finding a clinician with genuine expertise in research peptide pharmacology is harder than finding one willing to accept payment, and is worth the effort. Cost at the advanced stage is substantial. Research-peptide humanin is expensive — a daily 5-10 mg dose over 20 weeks can cost $2,000-$5,000 depending on vendor, which combined with other stacked peptides can bring annual protocol costs into the $15,000-$30,000+ range. This level of expenditure on unvalidated interventions displaces resources from validated health investments (high-quality food, training, sleep optimization, preventive screening, therapy, stress management) that have better evidence bases. Advanced users should periodically ask whether the peptide protocol is actually producing measurable benefit justifying its cost, or whether inertia and sunk-cost reasoning is maintaining the protocol past the point of value. The advanced stage is also where protocol de-escalation becomes appropriate. Humanin does not need to be continued indefinitely, and reducing the intervention count or discontinuing entirely when baseline health is optimized is a valid strategy. The goal of longevity intervention is long-term health, not maximal peptide stacking, and the discipline of knowing when to stop is as important as the willingness to start.